Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01416649 · ClinicalTrials.gov registry record
Impact of Exenatide on Sleep Duration
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 8
- Enrollment target
NCT01416649: Completed study, sponsored by University of Chicago.
NCT01416649 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01416649 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
This study investigates the effect of exenatide, a FDA approved medication for the treatment of type 2 diabetes on sleep duration and quality. Individuals with type 2 diabetes will be studied before and during treatment with Exenatide. Enrolled individuals will be asked to come to the University of Chicago for 3-4 outpatient visits over the course of 3-4 months.
Primary Outcome
Sleep duration and efficiency will be measured using an activity monitor worn on the wrist.
Interventions
- DRUG Exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-02-01 |
| Est. Completion | 2021-04-21 |
What the finished NCT01416649 record still lists
NCT01416649 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Exenatide is the first listed.
NCT01416649 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01416649 about?
NCT01416649 is a clinical study titled "Impact of Exenatide on Sleep Duration". This study investigates the effect of exenatide, a FDA approved medication for the treatment of type 2 diabetes on sleep duration and quality. Individuals with type 2 diabetes will be studied before and during treatment with Exenatide. Enrolled individuals will be asked to come to the University of...
What is the current status of trial NCT01416649?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2011-02-01. Estimated completion is 2021-04-21.
What interventions are being tested in trial NCT01416649?
The interventions under investigation include: Exenatide (DRUG).
Who is sponsoring clinical trial NCT01416649?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI